GI-MAP Microbial Assay Plus
The GI-MAP is the first and only gut test in the world to be running full quantitative PCR (qPCR) on multiple GI targets, including pathogens, bacteria, worms, yeasts, parasites and comprehensive antibiotic resistant genes, alongside intestinal health and immune markers.
The GI-MAP was designed to assess a patient's microbiome from a single stool sample, with particular attention to microbes that cause disease or that disrupt normal microbial balance and contribute to perturbations in the GI flora and contribute to illness. With full quantification, we can now see the level of infection thus, the GI-MAP arms the clinician with accurate, actionable clinical information.
- Pathogenic bacteria, toxins, parasites and viruses
- Commensal bacteria (inc. B.fragilis)
- Bacterial autoimmune triggers
- Dysbiotic bacteria
- Phyla microbiota ratios
- Opportunistic parasites
- Yeast, fungi and moulds
- Secretory IgA (sIgA)
- Anti-gliadin sIgA
- Pancreatic elastase 1
- Faecal Occult blood
- Antibiotic resistance genes
New Commensal MarkersAkkermansia mucinophila – Plays a significant role in the gut ecosystem by breaking down mucus polysaccharides. Low levels are associated with obesity and metabolic dysfunction, while high levels are linked to multiple sclerosis.
Clostridia (class*) – Important producers of short-chain fatty acids, and have many well-documented roles in promoting a healthy intestinal barrier, immune balance, and protection against pathogens.
Faecalibacterium prausnitzii – Well-known keystone species and a major butyrate producer. Many chronic inflammatory and autoimmune diseases have been associated with low levels of F. prausnitzii.
New Opportunistic Bacteria
Methanobacteriaceae (family) – Family of bacteria-like microbes that produce methane. High levels have been linked to chronic constipation, as well as some types of SIBO and IBS.
Fusobacterium spp. – Commonly found in the oral cavity, and may also be found in the intestine. Some are considered opportunistic pathogens, and may promote inflammatory processes and or advanced disease states.
For more information on the methodology and markers, please see the white paper, which has over 190 peer reviewed references.